Beam Therapeutics (BEAM) Competitors

Beam Therapeutics (NASDAQ:BEAM) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.

Which has more risk and volatility, BEAM or RGEN?

Beam Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Repligen has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of BEAM or RGEN?

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 4.2% of Beam Therapeutics shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the media prefer BEAM or RGEN?

In the previous week, Beam Therapeutics had 7 more articles in the media than Repligen. MarketBeat recorded 8 mentions for Beam Therapeutics and 1 mentions for Repligen. Repligen's average media sentiment score of 1.45 beat Beam Therapeutics' score of 1.18 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in BEAM or RGEN?

Repligen received 356 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 67.60% of users gave Repligen an outperform vote while only 54.64% of users gave Beam Therapeutics an outperform vote.

Company	Underperform	Outperform
Beam Therapeutics	Outperform Votes 53 54.64%	Underperform Votes 44 45.36%
Repligen	Outperform Votes 409 67.60%	Underperform Votes 196 32.40%

Which has better valuation & earnings, BEAM or RGEN?

Repligen has higher revenue and earnings than Beam Therapeutics. Repligen is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$349.64M	6.30	-$132.53M	-$1.76	-15.11
Repligen	$639.92M	12.74	$35.60M	-$0.37	-393.35

Do analysts recommend BEAM or RGEN?

Beam Therapeutics presently has a consensus target price of $47.67, suggesting a potential upside of 79.27%. Repligen has a consensus target price of $185.20, suggesting a potential upside of 27.25%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Repligen	0 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.62

Is BEAM or RGEN more profitable?

Repligen has a net margin of -3.36% compared to Beam Therapeutics' net margin of -41.07%. Repligen's return on equity of 3.90% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-41.07%	-16.22%	-10.94%
Repligen	-3.36%	3.90%	2.72%

Summary

Repligen beats Beam Therapeutics on 11 of the 19 factors compared between the two stocks.